Eprosartan

Drugbox
IUPAC_name = 4- [2-butyl-5-(2-carboxy-3-thiophen-2-yl-prop-1-enyl)-imidazol-1-yl] methyl] benzoic acid

---

CAS_number=133040-01-4
ATC_prefix=C09
ATC_suffix=CA02
ATC_supplemental=?
PubChem=9670
DrugBank=APRD00950
C=23 | H=24 | N=2 | O=4 | S=1
molecular_weight = Eprosartan mesylate: 520.625 g/mol
bioavailability= 15% (Eprosartan mesylate)
metabolism = not metabolized
elimination_half-life= 5 to 9 hours
excretion = Renal 10%, biliary 90%
pregnancy_category = ?
legal_status = ?
routes_of_administration= Oral

Eprosartan is an angiotensin II receptor antagonist used for the treatment of high blood pressure. It is marketed as Teveten by Abbott Laboratories in the United States and by Solvay Pharmaceuticals elsewhere. It is sometimes paired with hydrochlorothiazide, marketed in the US as Teveten HCT and elsewhere as Teveten Plus.

The drug acts on the renin-angiotensin system in two ways to decrease total peripheral resistance. First, it blocks the binding of angiotensin II to AT₁ receptors in vascular smooth muscle, causing vascular dilatation. Second, it inhibits sympathetic norepinephrine production, further reducing blood pressure.

As with other angiotensin II receptor antagonists, eprosartan is generally better tolerated than enalapril (an ACE inhibitor), especially among the elderly. [cite journal |author=Ruilope L, Jäger B, Prichard B |title=Eprosartan versus enalapril in elderly patients with hypertension: a double-blind, randomized trial |journal=Blood Press. |volume=10 |issue=4 |pages=223–9 |year=2001 |pmid=11800061 |doi=10.1080/08037050152669747]

External links

* [http://www.teveten.com/ Teveten website]

References